Keytruda (pembrolizumab)

P3, N=390, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting

P2, N=45, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Apr 2026 --> Apr 2027

P2, N=104, Recruiting, Fudan University | Suspended --> Recruiting

Talabostat plus pembrolizumab demonstrates preliminary anti-tumor activity in patients with relapsed SCNC. Further evaluation in a randomized study is warranted to assess the contribution of talabostat in this high-risk disease subset.

Approximately, 10-11% of patients were potentially misclassified by panels. These findings emphasize the importance of broader gene representation for accurate TMB determination near the clinical threshold-especially in tumor types lacking disease-specific ICI indications, where tissue-agnostic MSI-High/dMMR or TMB-High labeling represents the principal on-label route to ICI therapy.

A 78-year-old woman with Stage IV NSCLC (adenocarcinoma, no actionable mutations, PD-L1 negative) initially received carboplatin, pemetrexed, and pembrolizumab, complicated by neutropenic fever. She later enrolled in the SHERLOC trial (MM-121 + docetaxel), discontinued due to colitis and neutropenia...The patient received hydroxyurea, transfusion support, and tumor lysis prophylaxis...LC at the time of initial AML diagnosis is uncommon and portends poor prognosis. Clinicians should remain vigilant for new skin lesions and cytopenias in cancer survivors previously exposed to chemotherapy, as early recognition of extramedullary AML may expedite timely diagnosis and care planning.

This case illustrates herpes zoster reactivation during Pembrolizumab-based chemo-immunotherapy in metastatic NSCLC. It emphasizes the importance of systematically excluding infectious causes in new cutaneous eruptions under immunotherapy and supports multidisciplinary management. These findings also highlight the need to further explore VZV screening and vaccination strategies in cancer patients undergoing immunosuppressive treatments.

P2, N=22, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

P3, N=600, Not yet recruiting, Pfizer

P2, N=30, Recruiting, Yale University | Not yet recruiting --> Recruiting

The patient was treated with three courses of methylprednisolone pulse therapy (1000 mg/day × 3 days) over 7 months and fexofenadine, resulting in partial sweating recovery and CEA decline to 3.0 ng/mL. Pembrolizumab was continued throughout without interruption, and the patient maintained durable stable disease (SD) over approximately 45 months (alive at last follow-up). This case demonstrates the histopathological spectrum of ICI-induced AIGA from inflammation to fibrosis within a single patient, and highlights CEA elevation as both a diagnostic clue and a potential pitfall in oncological practice.

Coordinated expression of multiple inhibitory immune checkpoints identifies an inflamed tumor microenvironment associated with improved outcomes following PD-1 blockade in HNSCC.